Evidence map›Paper›PMID 35043276›Full record

ArticleJournal of neuro-oncology2022

MR susceptibility imaging for detection of tumor-associated macrophages in glioblastoma.

Amir Nazem, Samantha C Guiry, Mehrdad Pourfathi, Jeffrey B Ware, Hannah Anderson, Srikant Kamesh Iyer, Brianna F Moon, Yi Fan, Walter R Witschey, Rahim Rizi and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Clinical MR Biomarkers.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
  3. Review
  4. Article
  5. Magnetic resonance imaging-based radiomics for predicting infiltration levels of CD68+ tumor-associated macrophages in glioblastomas.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
    Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Amir Nazem *Department of Radiology, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, 1 Silverstein Building, 3400 Spruce St., Philadelphia, PA, 19104, USA.
Samantha C Guiry *Department of Radiology, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, 1 Silverstein Building, 3400 Spruce St., Philadelphia, PA, 19104, USA.
Mehrdad PourfathiDepartment of Radiology, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, 1 Silverstein Building, 3400 Spruce St., Philadelphia, PA, 19104, USA.
Jeffrey B WareDepartment of Radiology, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, 1 Silverstein Building, 3400 Spruce St., Philadelphia, PA, 19104, USA.
Hannah AndersonDepartment of Radiology, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, 1 Silverstein Building, 3400 Spruce St., Philadelphia, PA, 19104, USA.
Srikant Kamesh IyerDepartment of Radiology, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, 1 Silverstein Building, 3400 Spruce St., Philadelphia, PA, 19104, USA.
Brianna F MoonDepartment of Radiology, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, 1 Silverstein Building, 3400 Spruce St., Philadelphia, PA, 19104, USA.
Yi FanDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Walter R WitscheyDepartment of Radiology, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, 1 Silverstein Building, 3400 Spruce St., Philadelphia, PA, 19104, USA.
Rahim RiziDepartment of Radiology, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, 1 Silverstein Building, 3400 Spruce St., Philadelphia, PA, 19104, USA.
Stephen J BagleyAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Arati DesaiAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Donald M O'RourkeAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Steven BremAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, 19104, USA.
MacLean Nasrallah *Division of Neuropathology, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Ali Nabavizadeh *Department of Radiology, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, 1 Silverstein Building, 3400 Spruce St., Philadelphia, PA, 19104, USA. ali.nabavizadeh@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0002-0380-4552
Hospital of the University of Pennsylvania · USTranslational Therapeutics (United States) · USMayo Clinic · USNew York Medical College · USUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTumor-associated macrophages (TAMs) are a key component of glioblastoma (GBM) microenvironment. Considering the differential role of different TAM phenotypes in iron metabolism with the M1 phenotype storing intracellular iron, and M2 phenotype releasing iron in the tumor microenvironment, we investigated MRI to quantify iron as an imaging biomarker for TAMs in GBM patients.

methods21 adult patients with GBM underwent a 3D single echo gradient echo MRI sequence and quantitative susceptibility maps were generated. In 3 subjects, ex vivo imaging of surgical specimens was performed on a 9.4 Tesla MRI using 3D multi-echo GRE scans, and R2* (1/T2*) maps were generated. Each specimen was stained with hematoxylin and eosin, as well as CD68, CD86, CD206, and L-Ferritin.

resultsSignificant positive correlation was observed between mean susceptibility for the tumor enhancing zone and the L-ferritin positivity percent (r = 0.56, p = 0.018) and the combination of tumor's enhancing zone and necrotic core and the L-Ferritin positivity percent (r = 0.72; p = 0.001). The mean susceptibility significantly correlated with positivity percent for CD68 (ρ = 0.52, p = 0.034) and CD86 (r = 0.7 p = 0.001), but not for CD206 (ρ = 0.09; p = 0.7). There was a positive correlation between mean R2* values and CD68 positive cell counts (r = 0.6, p = 0.016). Similarly, mean R2* values significantly correlated with CD86 (r = 0.54, p = 0.03) but not with CD206 (r = 0.15, p = 0.5).

conclusionsThis study demonstrated the potential of MR quantitative susceptibility mapping as a non-invasive method for in vivo TAM quantification and phenotyping. Validation of these findings with large multicenter studies is needed.

Indexed as

Brain NeoplasmsGlioblastomaMagnetic Resonance ImagingTumor-Associated MacrophagesAdultApoferritinsBiomarkersHumansIronReproducibility of ResultsApoferritinsBiomarkersIronGlioblastomaMRIQuantitative susceptibility mappingTumor-associated macrophages

Identifiers

PMID35043276
OpenAlexW4206630448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.